Victor Oluwatomiwa Ajekiigbe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victor Oluwatomiwa Ajekiigbe has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ikponmwosa Jude Ogieuhi
Siberian State Medical University
5 shared publications - Chidera Stanley Anthony
University of Calabar, Calabar, Nigeria
4 shared publications - Adewunmi Akingbola
Department of Public Health, University of Cambridge, Cambridge, England, UK
2 shared publications - Ibukun Oyebimpe Oyeleke
Obafemi Awolowo University, Ilesa, Nigeria
2 shared publications - Olufemi Akinmeji
Olabisi Onabanjo University, Sagamu, Nigeria
2 shared publications - Adedoyin Veronica Babalola
Faculty of Clinical Science, College of Medicine, University of Ibadan, Ibadan, Nigeria
1 shared publication
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 80
Primary congenital glaucoma in African children: a scoping review of treatment outcomes and barriers to care
Background: Primary congenital glaucoma (PCG) is an uncommon but serious cause of childhood visual loss. In African settings, children often present late, with advanced disease. However, the evidence on treatment outcomes and barriers to care has not yet been comprehensively mapped. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Web of Science, African Journals Online, and African Index Medicus for English-language studies published between January 2011 and January 2026. Eligible studies reported treatment approaches, outcomes, complications, or barriers to care for children with PCG in Africa. Findings were synthesized narratively. Results: Ten studies involving 746 eyes from Tanzania, Ghana, Nigeria, Senegal, Ethiopia, Egypt, and Tunisia were included. Most were retrospective single-center studies. Mean age at presentation, where reported, ranged from 4.8 ± 3.6 months in Nigeria to 2.7 years in Ethiopia, while mean age at diagnosis was reported as 4.4 months in Ghana and 19 months in Tanzania. Mean age at surgery was reported as 5.2 ± 2.9 months in the Nile Delta cohort in Egypt, 5.9 months in Tunisia, and 8.1 ± 5.9 months in Nigeria. Bilateral disease, corneal edema, enlarged corneal diameters, and raised intraocular pressure were commonly reported. Surgery was the main reported treatment approach. Combined trabeculotomy-trabeculectomy was commonly used in more advanced cases, while angle procedures were used when corneal clarity allowed. Postoperative intraocular pressure reduction was reported, and short- to medium-term surgical success ranged from 72.7% to 91.6%. Longer follow-up showed a decline from 91.6% at 1 year to 54.3% at 10 years in Tunisia. Visual outcomes were less consistent, and poor follow-up, delayed referral, limited surgical infrastructure, and cost were frequently reported barriers. Conclusion: PCG in African children remains marked by delayed diagnosis, advanced disease at presentation, and barriers to care. Improving outcomes will likely require earlier recognition, stronger referral and follow-up systems, wider access to pediatric glaucoma expertise, and more robust multicenter prospective research.
- 6 July 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 80
Open AccessPrimary congenital glaucoma in African children: a scoping review of treatment outcomes and barriers to care
Background: Primary congenital glaucoma (PCG) is an uncommon but serious cause of childhood visual loss. In African settings, children often present late, with advanced disease. However, the evidence on treatment outcomes and barriers to care has not yet been comprehensively mapped. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Web of Science, African Journals Online, and African Index Medicus for English-language studies published between January 2011 and January 2026. Eligible studies reported treatment approaches, outcomes, complications, or barriers to care for children with PCG in Africa. Findings were synthesized narratively. Results: Ten studies involving 746 eyes from Tanzania, Ghana, Nigeria, Senegal, Ethiopia, Egypt, and Tunisia were included. Most were retrospective single-center studies. Mean age at presentation, where reported, ranged from 4.8 ± 3.6 months in Nigeria to 2.7 years in Ethiopia, while mean age at diagnosis was reported as 4.4 months in Ghana and 19 months in Tanzania. Mean age at surgery was reported as 5.2 ± 2.9 months in the Nile Delta cohort in Egypt, 5.9 months in Tunisia, and 8.1 ± 5.9 months in Nigeria. Bilateral disease, corneal edema, enlarged corneal diameters, and raised intraocular pressure were commonly reported. Surgery was the main reported treatment approach. Combined trabeculotomy-trabeculectomy was commonly used in more advanced cases, while angle procedures were used when corneal clarity allowed. Postoperative intraocular pressure reduction was reported, and short- to medium-term surgical success ranged from 72.7% to 91.6%. Longer follow-up showed a decline from 91.6% at 1 year to 54.3% at 10 years in Tunisia. Visual outcomes were less consistent, and poor follow-up, delayed referral, limited surgical infrastructure, and cost were frequently reported barriers. Conclusion: PCG in African children remains marked by delayed diagnosis, advanced disease at presentation, and barriers to care. Improving outcomes will likely require earlier recognition, stronger referral and follow-up systems, wider access to pediatric glaucoma expertise, and more robust multicenter prospective research.
- Open Access
- 16 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Pulmonary artery denervation in pulmonary hypertension: mechanism, efficacy, and future directions
- 16 April 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessPulmonary artery denervation in pulmonary hypertension: mechanism, efficacy, and future directions
- Open Access
- 6 March 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 65
The impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions
The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.
- 6 March 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 65
Open AccessThe impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions
The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.
- Open Access
- 22 January 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 6
Congenital heart disease in Africa: a scoping review of socioeconomic impact and strategic recommendations
Introduction: Congenital heart disease (CHD) poses a significant yet under recognized public health challenge in Africa. Despite advancements in diagnosis and treatment globally, many African countries still have significantly high mortality due to limited facilities of health care, inadequate infrastructure and delays in the diagnosis and management. This scoping review explores the socioeconomic impact of CHD on families across Africa and evaluates current policies, healthcare interventions, and systemic challenges. Methods: A comprehensive scoping review was conducted using multiple academic databases, focusing on studies published in international and national articles in English that examined the socioeconomic, psychosocial, and healthcare dimensions of CHD in African settings. Thematic synthesis was applied to interpret findings and compare them with trends in other low-, middle-, and high-income countries. Results: Families affected by CHD in Africa face significant financial burdens due to out-of-pocket healthcare expenses, long travel distances for treatment, and insufficient health insurance coverage. These challenges often lead to catastrophic health expenditures, debt, and delayed treatment. Caregivers face of patients faces significant psychosocial distress, with elevated rates of anxiety, depression, and social isolation. Geographic and systemic disparities result in long wait times for surgery and limited access to cardiac care. Although successful models such as cardiac surgery missions, NGO-public partnerships, and regional training centers exist, their reach and sustainability remain limited. Current health policies by government lack integration of routine screening methods such as pulse oximetry, and most African nations lack national CHD registries and dedicated pediatric cardiac programs. Conclusion: CHD presents a major challenge in Africa, with profound financial, emotional, and systemic impacts on children and families. This review highlights the urgent need for improved infrastructure, early screening, and specialized care. Policy reforms, local cardiac centers, and involvement of stakeholders—including cultural leaders and international partners—are essential. Strengthening research on CHD outcomes and its socioeconomic effects will guide effective, equitable healthcare strategies across the continent.
- 22 January 2026
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 74 (1) , 6
Open AccessCongenital heart disease in Africa: a scoping review of socioeconomic impact and strategic recommendations
Introduction: Congenital heart disease (CHD) poses a significant yet under recognized public health challenge in Africa. Despite advancements in diagnosis and treatment globally, many African countries still have significantly high mortality due to limited facilities of health care, inadequate infrastructure and delays in the diagnosis and management. This scoping review explores the socioeconomic impact of CHD on families across Africa and evaluates current policies, healthcare interventions, and systemic challenges. Methods: A comprehensive scoping review was conducted using multiple academic databases, focusing on studies published in international and national articles in English that examined the socioeconomic, psychosocial, and healthcare dimensions of CHD in African settings. Thematic synthesis was applied to interpret findings and compare them with trends in other low-, middle-, and high-income countries. Results: Families affected by CHD in Africa face significant financial burdens due to out-of-pocket healthcare expenses, long travel distances for treatment, and insufficient health insurance coverage. These challenges often lead to catastrophic health expenditures, debt, and delayed treatment. Caregivers face of patients faces significant psychosocial distress, with elevated rates of anxiety, depression, and social isolation. Geographic and systemic disparities result in long wait times for surgery and limited access to cardiac care. Although successful models such as cardiac surgery missions, NGO-public partnerships, and regional training centers exist, their reach and sustainability remain limited. Current health policies by government lack integration of routine screening methods such as pulse oximetry, and most African nations lack national CHD registries and dedicated pediatric cardiac programs. Conclusion: CHD presents a major challenge in Africa, with profound financial, emotional, and systemic impacts on children and families. This review highlights the urgent need for improved infrastructure, early screening, and specialized care. Policy reforms, local cardiac centers, and involvement of stakeholders—including cultural leaders and international partners—are essential. Strengthening research on CHD outcomes and its socioeconomic effects will guide effective, equitable healthcare strategies across the continent.
- Open Access
- 27 January 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-16
Understanding Nigeria’s antibiotic resistance crisis among neonates and its future implications
- 27 January 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-16
Open AccessUnderstanding Nigeria’s antibiotic resistance crisis among neonates and its future implications